Stockreport

ImmunityBio: Why I Am Upgrading To A Buy For 2026 [Seeking Alpha]

ImmunityBio, Inc.  (IBRX) 
PDF IBRX reported 2025 product revenue of $113m, up 700% year-on-year, but losses remain heavy and commercial traction is not yet spectacular. Anktiva shows superior dura [Read more]